The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.
- device : Renal denervation (Symplicity Catheter System)
Phase: Phase 3
Ages Eligible For Study:
- Individual is ? 18 and ? 80 years old at time of randomization. - Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 2 weeks prior to screening) that is expected to be maintained without changes for at least 6 months. - Individual has an office systolic blood pressure (SBP) of ? 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit